Please note that as of June 27, 2022, this figure reflects counts and rates over a 4 week period.There may also be delays in receiving data on doses administered. The shaded area represents a period of time (lag time) where there may be delays in receiving and processing reporting forms.Up to and including MMM DD, 2021 all adverse event reports represented 0.056% of all doses administered. Although the cumulative number of adverse event reports continues to increase over time, so does the number of doses administered.As a result the reporting rates appear higher. This is due to historical updates and unavailable denominator data from some jurisdictions at the time of posting, as well as the vaccination campaign slowing down. The number of doses administered for this time period has decreased. Of COVID-19 vaccine adverse event reports received forĪnd total doses administered in a 4-week reporting period, up to and including MMM DD, 2021 (n= ) Figure 1 below shows the number and rate of COVID-19 adverse event reports by reporting period, as well as the cumulative number of reports. Overall, the rate of serious reports has remained low. Of the reports, were considered serious ( 11.0 reports per 100,000 doses administered). There have been a total of reports ( 56.0 reports per 100,000 doses administered) up to and including.The data on this page may undergo changes as more information about cases becomes available.
Doses administered used for reporting rate calculations have been adjusted to account for the delay between vaccination and reporting. The information on this page reflects detailed case information data from the Public Health Agency of Canada’s Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) and Health Canada’s Canada Vigilance program.Learn more about reporting adverse events. If you experience an adverse event following immunization with a COVID-19 vaccine in Canada, please contact your healthcare provider. 482 were considered non-serious (0.006% of bivalent COVID-19 doses administered) and 145 (0.002% of bivalent COVID-19 doses administered) were considered serious. Of the 54,569 individual reports, 627 were following a bivalent vaccine.A total of 97,597,702 vaccine doses have been administered in Canada as of March 3, 2023, including 8,191,329 bivalent doses.Of the individual reports ( of all doses administered), were considered serious ( of all doses administered).We’ll respond to any safety issues right away and will inform Canadians about any risks that arise in Canada. Health Canada, the Public Health Agency of Canada (PHAC), the provinces and territories, and manufacturers continue to closely monitor the safety of COVID-19 vaccines.Evidence indicates that the benefits of COVID-19 vaccines continue to outweigh the risks of the disease.Health Canada and PHAC will continue to monitor this issue closely. The signal has not been found in other vaccine safety monitoring systems in the USA nor in other countries, including Canada. This preliminary safety signal has prompted additional investigation into whether there is a safety concern between the Pfizer-BioNTech bivalent COVID-19 vaccine and ischemic stroke in people 65 years of age and over. Food and Drug Administration (FDA) on findings from the Vaccine Safety Datalink. Health Canada and PHAC are aware of an updated report released on Monday Februby the Centers for Disease Control and Prevention (CDC) and the U.S.No new safety signals have been identified during this reporting period.Total adverse event following immunization reports that were serious
0 kommentar(er)
